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Combinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the
majority of treatment-na€ıve patients. Mass treatment programs to cure HCV in developing
countries are only feasible if the costs of treatment and laboratory diagnostics are very
low. This analysis aimed to estimate minimum costs of DAA treatment and associated
diagnostic monitoring. Clinical trials of HCV DAAs were reviewed to identify combina-
tions with consistently high rates of sustained virological response across hepatitis C geno-
types. For each DAA, molecular structures, doses, treatment duration, and components of
retrosynthesis were used to estimate costs of large-scale, generic production. Manufactur-
ing costs per gram of DAA were based upon treating at least 5 million patients per year
and a 40% margin for formulation. Costs of diagnostic support were estimated based on
published minimum prices of genotyping, HCV antigen tests plus full blood count/clinical
chemistry tests. Predicted minimum costs for 12-week courses of combination DAAs with
the most consistent efficacy results were: US$122 per person for sofosbuvir1daclatasvir;
US$152 for sofosbuvir1ribavirin; US$192 for sofosbuvir1ledipasvir; and US$115 for
MK-87421MK-5172. Diagnostic testing costs were estimated at US$90 for genotyping
US$34 for two HCV antigen tests and US$22 for two full blood count/clinical chemistry
tests. Conclusions: Minimum costs of treatment and diagnostics to cure hepatitis C virus
infection were estimated at US$171-360 per person without genotyping or US$261-450
per person with genotyping. These cost estimates assume that existing large-scale
treatment programs can be established. (HEPATOLOGY 2015;61:1174-1182)
T
reatment scaleup for the estimated 150 million
people infected with hepatitis C virus (HCV)
remains an unresolved public health challenge,
and up to 500,000 people die annually as a result of
HCV-related liver complications.1,2 For widespread
treatment of HCV in low- and middle-income coun-
tries (LMICs) to be feasible, short-course antiviral treat-
ments need to be available at very low costs. Several
combinations of direct-acting antivirals (DAAs) have
been recently licensed or are being developed that can
cure HCV in the majority of treatment-na€ıve patients
for a range of genotypes. These drugs generally have a
good safety profile and rates of sustained virological
response (SVR) close to 100%, including in tradition-
ally difficult-to-treat patients. The promising clinical
trial results for these DAAs suggest they will eventually
replace current interferon (IFN)-based treatment.3
The U.S. launch prices for a 12-week course of the
recently approved DAAs, sofosbuvir and simeprevir, are
US$84,000 and US$66,000, respectively.4 At these pri-
ces, treatment would be out of reach for the majority of
those in need in LMICs, and these medications would
need to be rationed in many high-income settings.3
However, we have previously estimated that minimum
production costs of sofosbuvir and simeprevir could be
as low as US$68-136 and US$130-270, respectively,
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with economies of scale.5 Achieving these low prices is
necessary to facilitate treatment scaleup.
The ability to diagnose and monitor HCV simply
and inexpensively will be important to ensure wide-
spread access to HCV treatment. At present, because
of the limited efficacy and poor tolerability profile of
current treatments, HCV diagnosis and monitoring
requires a range of complex tests before and during
treatment, including genotyping, HCV-RNA quantifi-
cation by polymerase chain reaction (PCR) assays, and
FibroScan to evaluate severity of liver disease.6 Most
resource-limited settings are not equipped to undertake
complex laboratory diagnostics at scale. Furthermore,
with current treatments, regimen duration and rates of
treatment success are highly dependent on the infect-
ing genotype, which varies significantly in its relative
prevalence worldwide.7 Encouragingly, the improved
side-effect profile and high SVR rates of new DAAs
should allow for simplification of both diagnosis and
monitoring of patients and may offer the potential for
a standardized package of care of patients.8
DAAs for HCV infection have similar chemical
structures and mechanisms of action to antiretrovirals
(ARVs) used for the treatment of human immunodefi-
ciency virus (HIV) infection. Generic ARVs are cur-
rently manufactured at a very low cost, covering
treatment for over 10 million people in LMICs. ARV
prices have fallen progressively through generic compe-
tition, economies of scale from more people treated,
and improved efficiencies in procurement of raw mate-
rials and production processes for active pharmaceuti-
cal ingredients (APIs).9,10 Recognizing the limited
laboratory infrastructure in resource-limited settings,
the public health approach to scaling up access to
treatment for HIV has relied on a minimal use of lab-
oratory investigations. In order to replicate the suc-
cesses of providing widespread ARV therapy, the
combined costs of HCV treatment and monitoring
will need to be substantially lowered.
Using the cost of HIV drugs as a framework for
analysis, we can make estimates for the potential cost of
HCV DAAs.3,5,11,12 This analysis aimed to estimate the
minimum costs of DAA treatment considered most
promising for large-scale treatment programs in LMICs
and associated diagnostic monitoring.
Materials and Methods
Clinical trials of HCV DAAs were reviewed to iden-
tify combinations with phase II or III trial results, good
safety profiles, high SVR rates, a future program of clin-
ical trials in different genotypes, and the potential to
reduce treatment duration. Three HCV DAAs—ledi-
pasvir (phase III), MK-8742 (phase III), and MK-5172
(Phase III)—were prioritized for further evaluation
based on this review. These DAAs were combined with
results from three previously studied drugs: sofosbuvir,
daclatasvir, and ribavirin.5 Table 1 shows summary SVR
rates for these combinations of DAAs, based on com-
bining the results of all published trials available.
Based on the chemical synthesis and molecular
structure, an approximate range of cost for the API of
each DAA was estimated. These calculations assumed
an API demand that would cover treatment for 5 mil-
lion people. Treating 5 million people was considered
the starting point for a volume demand large enough
to reasonably minimize API prices while assuming cost
pressures in the market through competition.
To determine the manufacturing cost, retrosynthetic
analysis of each target DAA into its precursor structures
and routes of chemical synthesis were taken from the
available literature. Additional considerations in assess-
ing the complexity of chemical synthesis included recog-
nizing the cost-limiting intermediates, number of steps
of synthesis, and availability/pricing of raw materials.5
From the manufacturing cost of an API, a 25%
markup as a profit margin for sales with an add-on of
40% for conversion to the finished pharmaceutical prod-
uct (FPP) was applied to estimate the overall predicted
unit cost per person. Estimated API costs for the selected
DAAs ranged from US$5,000-7,000 per kg. Because
these APIs are relatively expensive at the assumed volume
demand, a 40% markup was applied to estimate the cost
of the finished dosage form. These assumptions are based
on the method previously used to estimate minimum
production costs of other DAAs.5
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Using the daily dose of each DAA identified from
clinical trials, the total drug requirement for a 12-week
regimen was calculated. With these calculated produc-
tion costs per gram of DAA together with the total
amount of drug required, a minimum cost estimate
for a 12-week treatment course of each DAA was cal-
culated. Using these costs and the mid-point estimates
for ribavirin, daclatasvir, and sofosbuvir taken from a
previous analysis,5 the production costs of two-drug
combination regimens could be estimated based on the
combinations currently being studied in clinical trials
(Table 1).
Each trial for the chosen DAA combination regi-
mens was studied for treatment-related adverse events.
Using the safety profiles from these clinical trials, the
minimal necessary tests during treatment were pro-
posed as two full blood count and two clinical chemis-
try tests, taken before the start of treatment and then
at week 4 to monitor ongoing safety issues. Clinical
chemistry tests taken before treatment could also be
used for simple staging of liver disease (APRI/FIB4) to
guide decisions on the duration of DAA treatment.
Using the current literature on the analytical per-
formance characteristics of the available HCV diagnos-
tic tests, it was determined that the lab-based HCV
Architect antigen test could be a reasonable alternative
in comparison to HCV-RNA PCR for detecting HCV
RNA for diagnosis and post-treatment monitoring of
HCV patients. In this proposed system, a single anti-
gen test would be performed before the start of treat-
ment to confirm active HCV infection, and then a
second antigen test would be performed 6 months
after the end of treatment, to confirm that reinfection
or relapse had not occurred. Costs of diagnostic sup-
port were estimated based on published prices of tests
from developing countries.32,33
Using these estimates and the calculated production
costs of DAA combination regimens, an overall care
package for HCV diagnosis, treatment, and monitor-
ing was calculated.
Results
The DAAs, sofosbuvir, daclatasvir, ribavirin, ledipas-
vir, MK-8742, and MK-5172, were considered a prior-
ity for the cost analysis. Minimum costs of production
of sofosbuvir, daclatasvir, and ribavirin were estimated
in a previous analysis.5 Figure 1 shows these HCV
DAA structures as well as the route of synthesis and
raw materials in production for ledipasvir, MK-8742,
and MK-5172. A summary of the estimated cost per
person for a 12-week course of each HCV DAA is
shown in Table 2.5
MK-8742. MK-8742 is a tetracyclic indole-based
nonstructural (NS)5A inhibitor with a molecular
weight of 882 g/mol.34 At a 50-mg/day dose, a
12-week course of treatment will require 4.2 g of API.
Assuming 5 million patients would be treated, 21 met-
ric tonnes of API would be required. The cost-limiting
monobrominated imidazole intermediate (compound
5) and the efficiencies attributed to obtaining chirally
pure API at a late stage in the synthesis add substantial
expense to the five-step synthesis of MK-8742. The
estimated manufacturing cost of MK-8742 FPP is
US$10.50/g, based on a nominal API manufacturing
cost of US$6,000/kg. At a daily dose of 50 mg, the
Table 1. Results From Clinical Trials: Arms Combined, Treatment Na€ıve, by Genotype
Combination Trial Genotype Treatment Arms SVR Rate
Daclatasvir1sofosbuvir AI444-04013 Combined 24wk Arms* 1 12wk (n5 41) 95% (SVR-24)
24wk (n5 29) 97% (SVR-24)
2 and 3 24wk (n5 30) 93% (SVR-24)
Sofosbuvir1ribavirin Combined QUANTUM14 and ELECTRON15,16 1 12wk (n5 69) 75% (SVR-12)
Combined POSITRON,17 VALENCE,18 FISSION,19 and PHOTON-120 2 12wk (n5 237) 94% (SVR-12)
Combined POSITRON,17 FISSION,19 and PHOTON-120 3 12wk (n5 323) 59% (SVR-12)
Ruane et al.21 4 12wk (n5 14) 79% (SVR-12)
Sofosbuvir1ribavirin Combined SPARE,22 QUANTUM,14 and PHOTON-120 1 24wk (n5 168) 73% (SVR-12)
VALENCE†18 3 24wk (n5 105) 93% (SVR-12)
Ruane et al.21 4 24wk (n5 14) 100% (SVR-12)
Sofosbuvir/ledipasvir Combined LONESTAR23 and ION-324 1 8wk (n5 235) 94% (SVR-12)
Combined LONESTAR,23 ION-1,25 ION-3,24 SYNERGY,26 and ERADICATE27 12wk (n5 544) 95% (SVR-12)
ION-125 24wk (n5 217) 97% (SVR-12)
ELECTRON-228 Cohort 1 3 12wk (n5 25) 64% (SVR-12)
MK-8742/MK-5172 C-WORTHY29-31 Combined 12wk arms 1 12wk (n5 103) 95% (SVR 4-24)
*Combined arms of sofosbuvir 3 7 days, then sofosbuvir1daclatasvir 3 23 weeks1 24-week sofosbuvir1daclatasvir.
†Excluding 12-week regimen for genotype 3.
Abbreviations: wk, week; SVR-4, undetectable hepatitis C virus RNA 4 weeks after finished treatment; SVR-12, undetectable hepatitis C virus RNA 12 weeks after
finished treatment; SVR-24, undetectable hepatitis C virus RNA 24 weeks after finished treatment.
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estimated production cost for 12 weeks per person-
treatment is thus estimated as US$44 per person.
MK-5172. MK-5172 is a macrocyclic NS3/4a
protease inhibitor with a molecular weight of 767 g/
mol and chemical formula of C38H50N6O9S.
35 At a
daily dose of 100 mg, 12 weeks of treatment require
8.4 g of API. Assuming 5 million patients would be
treated, 42 metric tonnes of API would be required.
Compounds 2 and 3 are relatively easy to make, and
compound 4 is commercially available and therefore
cheap. The yields for the most difficult steps of the
synthesis—forming the macrocyclicurethane-lactam—
are highly efficient. Even though compound 4 is rela-
tively expensive to make, it is incorporated in a high-
yielding last step.36 On 42 metric tonnes of volume
demand, the API is estimated to cost US$5,000/kg.
Fig. 1. HCV DAA structure and likely cost limiting materials in production.
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Accordingly, a 12-week treatment with MK-5172 has
an estimated cost of US$74 per person.
Ledipasvir. Ledipasvir is a NS5A inhibitor with
an unsymmetric benzimidazole-difluorofluorene-
imidazole core.37 At a daily dose of 90 mg, a 12-week
course of ledipasvir requires 7.6 g of API. This results
in an API demand of 38 metric tonnes to treat 5 mil-
lion patients. Fluorene is the ultimate starting material
for this synthesis, with a current price of US$4/kg.
Intermediates 4 and 6 for the synthesis of the API are
cost-limiting. Overall production costs for the FPP are
estimated at US$12.25/g from an API cost of
US$7,000/kg, giving an estimated cost per 12-week
course of US$93 per person.
Combination Regimens. Using the calculated
DAA drug prices, the estimated costs of the four most
effective combination regimens are shown in Table 3.
Previously published cost estimates for ribavirin, sofos-
buvir, and daclatasvir5 were combined with those of
the three new DAAs. The 12-week combination of
MK-8742 and MK-5172 has an estimated minimum
cost of US$118 per person. A 12-week course of
daclatasvir or ribavirin and sofosbuvir could cost
US$121 or US$149 per person-treatment, respectively.
A treatment course combining sofosbuvir and ledipas-
vir could cost US$129 for 8 week or US$193 for 12
weeks per person. For some patients or some regimens,
a 24-week treatment might be necessary, doubling the
estimated treatment costs from the 12-week regimen.
Diagnostic Testing. The favorable safety profile of
these DAA combinations suggests that safety monitor-
ing could be limited to two full blood count plus clin-
ical chemistry tests, including alanine transaminase and
creatinine, one pretreatment, and another during
treatment.
Results from validation studies indicate a correlation
between HCV viral load and antigen quantification,
irrespective of HCV genotype, when HCV RNA is
>2,000 IU/mL.38,39 Compared with HCV RNA, the
Architect antigen test was specific, user-friendly, and
less expensive.40,41 One limitation is the sensitivity,42,43
which corresponds to a lower limit of detection
(LLOD) of approximately 2,000-IU/mL HCV-RNA
levels.44,45 Given that the majority of HCV infections
and relapsers are associated with a high level of viremia
(>2,000 IU/mL),33,43 the HCV antigen assay is a
robust alternative to HCV-RNA PCR to confirm
chronic infection.42-44,46 The reduced sensitivity limits
its clinical utility for use during therapy, but could
prove to be useful in monitoring patients with virolog-
ical relapse or reinfection.
Monitoring could involve an HCV antigen test pre-
treatment to establish infection and a repeat test 6
months after stopping treatment to ensure that reinfec-
tion or relapse has not occurred. If treatment is not
pangenotypic, HCV genotyping could be added for
pretreatment monitoring. Diagnostic testing costs were
estimated at US$90 for genotyping, US$34 for two
HCV antigen tests, and US$22 for two full blood
count and clinical chemistry tests.32,33
Overall Costs. The minimum costs of treatment,
diagnostic monitoring, and genotyping to cure HCV
are shown in Fig. 2. Minimum costs per person range
from US$174 for 12 weeks of MK-8742 and MK-
5172 with no genotyping to US$444 for 24 weeks of
sofosbuvir plus ribavirin with genotyping.
Discussion
This analysis suggests that a 12-week IFN-free regi-
men supported by minimal diagnostic testing could
cost US$264-444 per person, if genotyping is
required. The use of pangenotypic drugs with no gen-
otyping could cost US$171-360 per person. Recogniz-
ing that specialist physician care and advanced
laboratory monitoring is not feasible at the scale
required to treat large numbers of patients in resource-
limited settings, this simplified, easy-to-administer, and
tolerable DAA treatment approach would enable HCV
to be managed at lower-level health facilities, thereby
facilitating widespread treatment access.3
Table 3. Predicted Costs of Key Drug Combinations
Regimen
Daily dose
(mg)
Duration
(Weeks)
Predicted
Unit
Cost (US$)
MK-87421MK-5172 501100 12 $118
Daclatasvir1sofosbuvir 601400 12 $121
24 $242
Sofosbuvir1ledipasvir 400190 8 $129
12 $193
Sofosbuvir1ribavirin 40011,200 12 $149
24 $298
Table 2. Predicted Minimum Costs of Selected HCV DAAs for
12 Weeks of Treatment
Agent Patent Expiry
Daily
Dose (mg)
Overall Dose
Per 12-wk (g)
Estimated
cost/g (US$)
Predicted
Cost (US$)
Ribavirin Generic 1,200 100.8 0.34* $48
Daclatasvir 2027 60 5.0 4.00 $20
MK-8742 2028 50 4.2 10.50 $44
Sofosbuvir 2029 400 33.6 3.00 $101
MK-5172 2030 100 8.4 8.75 $74
Ledipasvir 2030 90 7.6 12.25 $93
*Current mid-point cost of API from 3 Chinese suppliers.5
Abbreviation: wk, week.
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The cost of ARVs in LMICs is mainly driven by the
price of the API, which constitutes 65%-90% of the
total market price.10,11 Through increased volume
demand, cheaper raw materials, and improved chemi-
cal synthesis, the price of generic antiretroviral APIs
has significantly fallen over the last decade. For exam-
ple, generic manufacture of efavirenz API has fallen
from US$1,100 to US$130/kg over this period.10 This
suggests that there is an opportunity for future price
reductions for DAA APIs through these same mecha-
nisms.10,11 With this in mind, the estimates in this
analysis are based on moderate volume demand (5
million people treated per year) and are thus depend-
ent on sizeable procurement orders and the presence
of competition in the market as one mechanism to
encourage price reductions. There are a number of
pricing and procurement mechanisms that need to be
utilized in order to secure such orders, and this
depends on commitment to improving access to treat-
ment by a range of actors, including originator pharma-
ceutical companies, generic manufacturers, governments,
and donors.
The DAA patent holders (originator companies) are
likely to offer treatment to the poorest countries at a
discounted price—this is already the case for sofosbu-
vir.11 For other countries, the most commonly
observed marketing strategies include voluntary licens-
ing agreements to supply medicines to low-income
countries, negotiating terms of tiered pricing for
middle-income countries, and to maintain standard
pricing for those countries considered high-income.3
However, these strategies are unlikely to stimulate
the needed levels of access to those countries most
heavily burdened. Patents for these DAAs do
not expire until at least 2027, restricting generic
production until this time.47-50 In order to overcome
patents and allow for generic drug production, govern-
ments have invoked the Trade-Related Aspects of
Intellectual Property Rights (TRIPS) flexibilities to
overcome patent barriers and allow generic competi-
tion for ARVs and other essential medicines.3,12
Generic competition has been central to the decreas-
ing prices of HIV treatment and has mainly been
facilitated by patent opposition in India.51 Generic
drugs are generally considerably cheaper than the origi-
nator versions and, furthermore, remain at a constantly
low level for LMICs. Another option under the TRIPS
flexibilities is employing stricter standards for patent-
ability and opposing new applications.52 The patent
for sofosbuvir has received pregrant opposition on the
basis of lack of innovation, which, if approved, will
increase competition and help drive down the cost.
Such approaches could be employed to increase generic
access to other DAAs.
In addition to lowering drug costs, large-scale treat-
ment programs for HIV only became feasible after sig-
nificant support from international donors, including
the establishment of new funding mechanisms. Inter-
national donors continue to play a significant role in
financing the supply of HIV medicines. Owing to the
size of the potential orders, large donor organizations
also have more bargaining power than individual
countries, which will be pivotal in securing lower pri-
ces. While international funding for HCV programmes
is needed, it is also essential that governments begin to
allocate sustained financing for national HCV
programs.
The current analysis further suggests that the current
diagnostic and monitoring package could be substan-
tially simplified as a result of the improved side-effect
Fig. 2. Minimum costs of treat-
ment, diagnostic monitoring, and
genotyping. Abbreviations: DCV,
daclatasvir; LDV, ledipasvir; RBV,
ribavirin; SOF, sofosbuvir.
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profile and efficacy of DAA combinations observed in
clinical trials. Monitoring with a full blood count plus
clinical chemistry test (pretreatment and during treat-
ment) could be sufficient to monitor for side effects
and could cost in the region of US$22 per person. If
treatment is not pangenotypic, HCV genotyping could
be added to pretreatment monitoring.10 Although
qualitative viral load monitoring is desirable and
informative, current approaches are expensive and
technically complex; this limitation, together with the
high SVR rates in current DAA trials, brings into
question the necessity of repeated viral load monitor-
ing during treatment. Given that the majority of HCV
infections are associated with very high viral loads,
including in patients relapsing after treatment, a quali-
tative HCV antigen test could be sufficient to confirm
viral replication or suppression both pre- and post-
treatment.8,33,44 The HCV antigen assay is less expen-
sive and requires less technical expertise than PCR
assays; further evaluations regarding the LLOD are
required.40 New studies need to assess how often the
RNA levels are above the LLOD of 2,000 IU/mL
before treatment or at relapse/reinfection and to
confirm that the HCV-RNA and HCV antigen tests
provide comparable results.
This analysis has several limitations. The results of
clinical trials on the new DAAs are not representative
of all patient subpopulations in need of treatment.
Relatively few patients with genotypes 4-6 have been
included in clinical studies, despite these genotypes
predominating in certain regions of the world.8 The
high SVR rates for these new DAAs still need to be
confirmed in real-world situations outside clinical tri-
als.3 Most of these DAAs are only at phase III of
development or have only recently been approved.
Clinical trial populations are selective, and safety in
program settings may be different. All regimen cost
estimates in this analysis are based on a 12-week treat-
ment course. Shorter treatment durations would fur-
ther reduce estimated costs if efficacy is shown.
Conversely, for some of the currently approved DAA
regimens, some genotypes require 24 weeks of treat-
ment. In the future, when clinical trial results are avail-
able, the costs of sequences of treatment will be
required, including new or existing DAA treatments
for patients who relapse on their initial combina-
tions—these costings will need to be included in sub-
sequent analyses. Finally, the estimated costs do not
include the importation, transport, and distribution of
the drugs.
The HCV pipeline includes several other promising
candidates that may emerge as future treatment options.8
For example the new drug, GS-5816, is clinically active
against all genotypes. At a daily dose of 25-100 mg, a
12-week treatment course would only require between 2
and 8 g of API.
In summary, minimum costs of treatment and diag-
nostics to cure HCV were estimated at US$174-354
per person without genotyping and US$264-444 per
person with genotyping. These costs assume that large-
scale treatment programs can be established for HCV,
similar to those implemented for HIV/acquired
immune deficiency syndrome. Treatments with proven
pangenotypic activity will be required to avoid expen-
sive pretreatment genotyping, and further reductions
in price could be achieved through shorter durations
of treatment, if efficacy is proven.
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